These data support the findings described in "Impact of molecular tumour board discussion on targeted therapy allocation in prostate cancer" by Slootbeek et al. All data traceable to patients (eg. date of birth) is excluded from the dataset.The data contains 277 prostate cancer patients discussed in a molecular tumour board (MTB) at the Radboudumc, Nijmegen. A genetically matched therapy was recommended by the MTB to 102 patients. For those patients, the genetic alteration that formed the rationale for the recommendation is also made available. Sixty-three of the 102 patients initiated their recommended therapy of which almost half had a progression-free survival of more than six months. Other findings are described in the main article.